Immunotherapy of chronic inflammatory demyelinating polyradiculoneuropathy

Bibliography

• Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989;46:878-84
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Prineas JW, Pollard JD. Chronic inflammatory demyelinating polyradiculoneuropathy. In: Dyck PJ, Thomas PK, Griffin JW, et al., editors. Peripheral neuropathy. 3rd edition. Toronto; Saunders Book Company; 1993
   Google Scholar
• Van Doorn PA, Rossi F, Brand A, et al. On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1990;29:57-64
   PubMed Web of Science ®Google Scholar
• Lunn MP, Manji H, Choudhary PP, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 1999;66:677-80
   PubMed Web of Science ®Google Scholar
• McLeod JG, Pollard JD, Macaskill P, et al. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999;46:910-3
   PubMed Web of Science ®Google Scholar
• Chio A, Cocito D, Bottacchi E, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiologic study in Italy. J Neurol Neurosurg Psychiatry 2007
   Google Scholar
• Van der Meche FG, Van Doorn PA. Chronic inflammatory demyelinating polyneuropathy (CIDP). Electroencephalogr Clin Neurophysiol Suppl 1999;50:493-8
   PubMedGoogle Scholar
• Hughes RA, Bouche P, Cornblath DR, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006;13:326-32
   PubMed Web of Science ®Google Scholar
• Hughes RA, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2006;11:30-46
   PubMed Web of Science ®Google Scholar
• Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991;41:617-8
   PubMed Web of Science ®Google Scholar
• Meyer Zu HG, Hartung HP, Kieseier BC. From bench to bedside – experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol 2007;3:198-211
   PubMedGoogle Scholar
• Koller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005;352:1343-56
   PubMed Web of Science ®Google Scholar
• Iijima M, Yamamoto M, Hirayama M, et al. Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology 2005;64:1471-5
   PubMed Web of Science ®Google Scholar
• Austin JH. Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain 1958;81:157-92
   PubMed Web of Science ®Google Scholar
• Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005;44:61-98
   PubMed Web of Science ®Google Scholar
• Scudeletti M, Lanza L, Monaco E, et al. Immune regulatory properties of corticosteroids: prednisone induces apoptosis of human T lymphocytes following the CD3 down-regulation. Ann NY Acad Sci 1999;876:164-79
   PubMed Web of Science ®Google Scholar
• Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 2005;62:249-54
   PubMed Web of Science ®Google Scholar
• Molenaar DS, Van Doorn PA, Vermeulen M. Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. J Neurol Neurosurg Psychiatry 1997;62:388-90
   PubMed Web of Science ®Google Scholar
• Bromberg MB, Carter O. Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-based data. Muscle Nerve 2004;30:20-37
   PubMed Web of Science ®Google Scholar
• Leussink VI, Jung S, Merschdorf U, et al. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol 2001;58:91-7
   PubMed Web of Science ®Google Scholar
• Dyck PJ, O'Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982;11:136-41
   PubMed Web of Science ®Google Scholar
• Mehndiratta MM, Hughes RA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002:CD002062
   Google Scholar
• Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Engel WK. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol 1981;9(Suppl):134-45
   PubMed Web of Science ®Google Scholar
• McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987;110:1617-30
   PubMed Web of Science ®Google Scholar
• Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med 1976;84:304-15
   PubMed Web of Science ®Google Scholar
• Van Schaik IN, Winer JB, de Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. Lancet Neurol 2002;1:491-8
   PubMed Web of Science ®Google Scholar
• Donaghy M, Mills KR, Boniface SJ, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1994;57:778-83
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003;349:831-6
   PubMed Web of Science ®Google Scholar
• Vermeulen M, Van der Meche FG, Speelman JD, et al. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci 1985;70:317-26
   PubMed Web of Science ®Google Scholar
• Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-55
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002;59:S13-21
   PubMedGoogle Scholar
• Van Schaik IN, Vermeulen M, Brand A. In vitro effects of polyvalent immunoglobulin for intravenous use. J Neurol Neurosurg Psychiatry 1994;57(Suppl):15-7
   PubMed Web of Science ®Google Scholar
• Kurlander RJ, Hall J. Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest 1986;77:2010-8
   PubMed Web of Science ®Google Scholar
• Misra N, Bayry J, Ephrem A, et al. Intravenous immunoglobulin in neurological disorders: a mechanistic perspective. J Neurol 2005;252(Suppl 1):I1-6
   PubMedGoogle Scholar
• Van Schaik IN, Winer JB, de Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002:CD001797
   Google Scholar
• Faed JM, Day B, Pollock M, et al. High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology 1989;39:422-5
   PubMed Web of Science ®Google Scholar
• Cornblath DR, Chaudhry V, Griffin JW. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol 1991;30:104-6
   PubMed Web of Science ®Google Scholar
• Van Doorn PA, Vermeulen M, Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol 1991;48:217-20
   PubMed Web of Science ®Google Scholar
• Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996;119(Pt 4):1067-77
   PubMed Web of Science ®Google Scholar
• Thompson N, Choudhary P, Hughes RA, Quinlivan RM. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1996;243:280-5
   PubMed Web of Science ®Google Scholar
• Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56:445-9
   PubMed Web of Science ®Google Scholar
• Vermeulen M, Van Doorn PA, Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993;56:36-9
   PubMed Web of Science ®Google Scholar
• ICE Study Group. Immune globulin intravenous, 10% caprylate/chromatography purified for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) efficacy study. Abstracts of the 132nd Annual Meeting of the American Neurological Association; 2007 October 7 – 10; Washington, DC, USA. Ann Neurol 2007;62(Suppl 11):S1-83, abstract T-81
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-45
   PubMed Web of Science ®Google Scholar
• Van Doorn PA, Dippel DWJ, Vermeulen M. Longterm iv immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy [abstract]. J Peripher Nerv Syst 2007;12(Suppl):89
   Google Scholar
• Kubori T, Mezaki T, Kaji R, et al. The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. No To Shinkei 1999;51:127-35
   PubMedGoogle Scholar
• Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 1999;22:1479-97
   PubMed Web of Science ®Google Scholar
• Van der Meche FG, Van Doorn PA. Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies. Ann Neurol 1995;37(Suppl 1):S14-31
   PubMedGoogle Scholar
• Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121:259-62
   PubMed Web of Science ®Google Scholar
• Debes A, Bauer M, Kremer S. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study. Pharmacoepidemiol Drug Saf 2007;16:1038-47
   PubMed Web of Science ®Google Scholar
• Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf 1999;21:171-85
   PubMed Web of Science ®Google Scholar
• Brettle RP, Gross M, Legg NJ, et al. Treatment of acute polyneuropathy by plasma exchange. Lancet 1978;2:1100
   PubMed Web of Science ®Google Scholar
• Levy RL, Newkirk R, Ochoa J. Treating chronic relapsing Guillain-Barre syndrome by plasma exchange. Lancet 1979;2:259-60
   PubMed Web of Science ®Google Scholar
• Server AC, Lefkowith J, Braine H, McKhann GM. Treatment of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange. Ann Neurol 1979;6:258-61
   PubMed Web of Science ®Google Scholar
• Heininger K, Liebert UG, Toyka KV, et al. Chronic inflammatory polyneuropathy. Reduction of nerve conduction velocities in monkeys by systemic passive transfer of immunoglobulin G. J Neurol Sci 1984;66:1-4
   PubMed Web of Science ®Google Scholar
• Mehndiratta MM, Hughes RA, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004:CD003906
   Google Scholar
• Dyck PJ, Daube J, O'Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;314:461-5
   PubMed Web of Science ®Google Scholar
• Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996;119:1055-66
   PubMed Web of Science ®Google Scholar
• Zinman LH, Sutton D, Ng E, et al. A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy. Transfus Apher Sci 2005;33:317-24
   PubMed Web of Science ®Google Scholar
• Norda R, Stegmayr BG. Therapeutic apheresis in Sweden: update of epidemiology and adverse events. Transfus Apher Sci 2003;29:159-66
   PubMed Web of Science ®Google Scholar
• Kiprov DD, Golden P, Rohe R, et al. Adverse reactions associated with mobile therapeutic apheresis: analysis of 17,940 procedures. J Clin Apher 2001;16:130-3
   PubMed Web of Science ®Google Scholar
• Hughes RA, Swan AV, Van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004:CD003280
   Google Scholar
• Dyck PJ, O'Brien P, Swanson C, et al. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 1985;35:1173-6
   PubMed Web of Science ®Google Scholar
• Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998;50:1778-83
   PubMed Web of Science ®Google Scholar
• Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000:CD000067
   PubMedGoogle Scholar
• Fialho D, Chan YC, Allen DC, et al. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. J Neurol Neurosurg Psychiatry 2006;77:544-7
   PubMed Web of Science ®Google Scholar
• Yazici Y, Sokka T, Kautiainen H, et al. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005;64:207-11
   PubMed Web of Science ®Google Scholar
• Mowzoon N, Sussman A, Bradley WG. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001;185:119-22
   PubMed Web of Science ®Google Scholar
• Radziwill AJ, Schweikert K, Kuntzer T, et al. Mycophenolate mofetil for chronic inflammatory demyelinating polyradiculoneuropathy: an open-label study. Eur Neurol 2006;56:37-8
   PubMed Web of Science ®Google Scholar
• Umapathi T, Hughes R. Mycophenolate in treatment-resistant inflammatory neuropathies. Eur J Neurol 2002;9:683-5
   PubMed Web of Science ®Google Scholar
• Benedetti L, Grandis M, Nobbio L, et al. Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. Muscle Nerve 2004;29:748-9
   PubMed Web of Science ®Google Scholar
• Chaudhry V, Cornblath DR, Griffin JW, et al. A safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:94-6
   PubMed Web of Science ®Google Scholar
• Gorson KC, Amato AA, Ropper AH. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004;63:715-7
   PubMed Web of Science ®Google Scholar
• Prineas JW, McLeod JG. Chronic relapsing polyneuritis. J Neurol Sci 1976;27:427-58
   PubMed Web of Science ®Google Scholar
• Brannagan TH III, Pradhan A, Heiman-Patterson T, et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002;58:1856-8
   PubMed Web of Science ®Google Scholar
• Good JL, Chehrenama M, Mayer RF, Koski CL. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 1998;51:1735-8
   PubMed Web of Science ®Google Scholar
• Barnett MH, Pollard JD, Davies L, McLeod JG. Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1998;21:454-60
   PubMed Web of Science ®Google Scholar
• Matsuda M, Hoshi K, Gono T, et al. Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 2004;224:29-35
   PubMed Web of Science ®Google Scholar
• Mahattanakul W, Crawford TO, Griffin JW, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. J Neurol Neurosurg Psychiatry 1996;60:185-7
   PubMed Web of Science ®Google Scholar
• Odaka M, Tatsumoto M, Susuki K, et al. Intractable chronic inflammatory demyelinating olyneuropathy treated successfully with ciclosporin. J Neurol Neurosurg Psychiatry 2005;76:1115-20
   PubMed Web of Science ®Google Scholar
• Hodgkinson SJ, Pollard JD, McLeod JG. Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 1990;53:327-30
   PubMed Web of Science ®Google Scholar
• Visudtibhan A, Chiemchanya S, Visudhiphan P. Cyclosporine in chronic inflammatory demyelinating polyradiculoneuropathy. Pediatr Neurol 2005;33:368-72
   PubMed Web of Science ®Google Scholar
• Briani C, Zara G, Zambello R, et al. Rituximab-responsive CIDP. Eur J Neurol 2004;11:788
   PubMed Web of Science ®Google Scholar
• Knecht H, Baumberger M, Tobon A, Steck A. Sustained remission of CIDP associated with Evans syndrome. Neurology 2004;63:730-2
   PubMed Web of Science ®Google Scholar
• Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007;35:66-9
   PubMed Web of Science ®Google Scholar
• Hirst C, Raasch S, Llewelyn G, Robertson N. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). J Neurol Neurosurg Psychiatry 2006;77:800-2
   PubMed Web of Science ®Google Scholar
• Chin RL, Sherman WH, Sander HW, et al. Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2003;210:19-21
   PubMed Web of Science ®Google Scholar
• Richez C, Blanco P, Lagueny A, et al. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-α blockers. Neurology 2005;64:1468-70
   PubMed Web of Science ®Google Scholar
• Ahlmen J, Andersen O, Hallgren G, Peilot B. Positive effects of tacrolimus in a case of CIDP. Transplant Proc 1998;30:4194
   PubMed Web of Science ®Google Scholar
• De Weerdt A, Claeys KG, De Jonghe P, et al. Case report and review of the literature. Clin Neurol Neurosurg 2007;110:291-4
   PubMed Web of Science ®Google Scholar
• Hadden RD, Sharrack B, Bensa S, et al. Randomized trial of interferon β-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999;53:57-61
   PubMed Web of Science ®Google Scholar
• Kuntzer T, Radziwill AJ, Lettry-Trouillat R, et al. Interferon-β1a in chronic inflammatory demyelinating polyneuropathy. Neurology 1999;53:1364-5
   PubMed Web of Science ®Google Scholar
• Vallat JM, Hahn AF, Leger JM, et al. Interferon beta-1a as an investigational treatment for CIDP. Neurology 2003;60:S23-8
   PubMedGoogle Scholar
• Ropper A. Safety and efficacy of avonex in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00099489?term=Ropper&rank=2 [Last accessed 6 March 2008]
   Google Scholar
• Cocco E, Mamusa E, Carboni N, et al. Treatment of refractory chronic inflammatory demyelinating polyneuropathy with interferon β1B. J Neurol 2005;252:1420-2
   PubMed Web of Science ®Google Scholar
• Pirko I, Kuntz NL, Patterson M, et al. Contrasting effects of IFNβ and IVIG in children with central and peripheral demyelination. Neurology 2003;60:1697-9
   PubMed Web of Science ®Google Scholar
• Matsuse D, Ochi H, Tashiro K, et al. Exacerbation of chronic inflammatory demyelinating polyradiculoneuropathy during interferonβ-1b therapy in a patient with childhood-onset multiple sclerosis. Intern Med 2005;44:68-72
   PubMed Web of Science ®Google Scholar
• Gorson KC, Ropper AH, Clark BD, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-α 2a. Neurology 1998;50:84-7
   PubMed Web of Science ®Google Scholar
• Pavesi G, Cattaneo L, Marbini A, et al. Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy. J Neurol 2002;249:777-9
   PubMed Web of Science ®Google Scholar
• Vermeulen M, Van Oers MH. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2002;72:127-8
   PubMed Web of Science ®Google Scholar
• Vermeulen M, Van Oers MH. Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation. J Neurol Neurosurg Psychiatry 2007;78:1154
   PubMed Web of Science ®Google Scholar
• Mahdi-Rogers M, Hughes RA, Kazmi M, Ferner R. Autologous peripheral blood progenitor cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2007;12(Suppl):55
   Google Scholar
• Remenyi P, Masszi T, Borbenyi Z, et al. CIDP cured by allogeneic hematopoietic stem cell transplantation. Eur J Neurol 2007;14:e1-2
   PubMed Web of Science ®Google Scholar
• Burt, R. Hematopoietic stem cell support in chronic inflammatory demyelinating polyneuropathy. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00278629?term=Burt&rank=10 [Last accessed 6 March 2008]
   Google Scholar
• Kapoor S, Wilson AG, Sharrack B, et al. Haemopoietic stem cell transplantation – an evolving treatment for severe autoimmune and inflammatory diseases in rheumatology, neurology and gastroenterology. Hematology 2007;12:179-91
   PubMed Web of Science ®Google Scholar
• Gardulf A, Andersen V, Bjorkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995;345:365-9
   PubMed Web of Science ®Google Scholar
• Koller H, Schroeter M, Feischen H, et al. Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol 2006;253:1505-6
   PubMed Web of Science ®Google Scholar
• Lee DH, Linker RA, Paulus W, et al. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2007
   Google Scholar